BLZ495X
Total Payments
$45,906
Transactions
10
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $1,111 | 6 | 3 |
| 2019 | $2,500 | 1 | 0 |
| 2018 | $35,095 | 2 | 0 |
| 2017 | $7,200 | 1 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $45,906 | 10 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A PHASE I AND OR II OPEN LABEL MULTI CENTER STUDY OF THE SAFETY AND EFFICACY OF BLZ945 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULTS PATIENTS WITH ADVANCED SOLID TUMORS | Novartis Pharmaceuticals Corporation | $44,964 | 0 |
| RESEARCH RELATED PUBLICATIONS SUPPORT | Novartis Pharmaceuticals Corporation | $942.00 | 3 |
Ad
Manufacturing Companies
Product Information
- Type Drug
- Total Payments $45,906
- Total Doctors 3
- Transactions 10
About BLZ495X
BLZ495X is a drug associated with $45,906 in payments to 3 healthcare providers, recorded across 10 transactions in the CMS Open Payments database. The primary manufacturer is Novartis Pharmaceuticals Corporation.
Payment data is available from 2017 to 2020. In 2020, $1,111 was paid across 6 transactions to 3 doctors.
The most common payment nature for BLZ495X is "Unspecified" ($45,906, 100.0% of total).
BLZ495X is associated with 2 research studies, including "A PHASE I AND OR II OPEN LABEL MULTI CENTER STUDY OF THE SAFETY AND EFFICACY OF BLZ945 AS SINGLE AGENT AND IN COMBINATION WITH PDR001 IN ADULTS PATIENTS WITH ADVANCED SOLID TUMORS" ($44,964).